<DOC>
	<DOCNO>NCT01887691</DOCNO>
	<brief_summary>The purpose study examine influence sleep effectiveness glucose insulin metabolism health disease ( prediabetes type two diabetes ) . We monitor sleep effectiveness use sleep spectrogram , obtain serial nocturnal blood glucose insulin measurement , assess impact pharmacologic enhancement [ use eszopiclon ( Lunesta ) , medication promotes stable sleep ) ] glucose insulin homeostasis . We hypothesize 1 : Effective sleep associate enhanced insulin sensitivity , relative ineffective sleep state , 2 : Enhancing sleep effectiveness use eszopiclone ( Lunesta ) improve 24-hour glucose metabolism prediabetics diabetic compare baseline .</brief_summary>
	<brief_title>Sleep Effectiveness Insulin Glucose Homeostasis</brief_title>
	<detailed_description>Evidence experimental study support hypothesis fragment insufficient sleep contributes impair glucose insulin homeostasis . The sleep spectrogram , EEG-independent measure sleep effectiveness , map couple oscillation heart rate variability ECG-derived respiration . In sample non-diabetic subject without sleep apnea , previously explore association ECG-spectrogram derive biomarkers glucose metabolism find marker effective sleep , High Frequency Coupling ( HFC ) , associate reduce diabetes risk ( increase Disposition Index ) . HFC also enhance sedative medication ( unpublished data ) . In study 1 . ) explore relationship sleep effectiveness insulin sensitivity across sleep period , frequently sample glucose insulin nocturnal polysomnography healthy prediabetic subject ; 2 . ) evaluate impact pharmacologic enhancement effective sleep nightly eszopiclone ( 1 week , home environment ) glycemic profile ( continuous glucose monitoring , 72 hr ) prediabetics diabetic compare pretreatment baseline . We expect desirable glycemic profile correlate spectrographic marker effective sleep undesirable glucose profile correlate marker ineffective sleep . Using pharmacologic enhancement effective sleep , expect demonstrate improvement glycemic profile prediabetic diabetic subject compare pre-treatment baseline .</detailed_description>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Eszopiclone</mesh_term>
	<criteria>Healthy volunteer , men woman 1864 year age . Fluent English speaker . Health status per criterion list prediabetes diabetes ( base 2003 American Diabetes Association criterion 2009 International Expert Committee Report : Prediabetics impair glucose tolerance fast plasma glucose ( FPG ) 100125 mg/dL , Hemoglobin A1C 5.76.4 % , 2hour plasma glucose ( PG ) 140199 mg/dL 75g oral glucose tolerance test ( OGTT ) . Diabetics FPG ≥ 126 mg/dL , Hemoglobin A1C ≥ 6.5 % , 2hour PG ≥ 200 mg/dL OGTT . Primary psychiatric disease condition may independently contribute sleep fragmentation may hinder subject 's ability complete propose testing : Respiratory , liver , clot disorder History sleep disorder breathing , Restless legs syndrome Periodic limb movement disorder high clinical suspicion sleep disorder breathe sleep disorder ( e.g. , snore , excessive daytime sleepiness , frequent napping , excessive motor activity ) Shift worker circadian phase disorder Abnormal resting ECG , pacemaker , atrial fibrillation arrhythmia Seizure disorder History depression , bipolar disorder , anxiety disorder , schizophrenia use psychiatric medication Narcolepsy Tobacco recreational drug use Pregnancy lactation Regular use stimulant hypnotic medication Evidence sleep apnea ( ApneaHypopnea Index &gt; 10 screen sleep study )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Prediabetic</keyword>
	<keyword>Prediabetes</keyword>
	<keyword>Glucose intolerance</keyword>
	<keyword>Sleep quality</keyword>
	<keyword>Continuous glucose monitoring</keyword>
	<keyword>Diabetes risk</keyword>
	<keyword>eszopiclone</keyword>
</DOC>